Business
RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
NEWPORT BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the filing of four novel patent applications for its two candidates EL-22 and EL-32. These patent applications cover the animal market, as well as treating muscle loss in obese patients, both as standalone and combination therapies alongside GLP-1 receptor agonists. The Company filed the
About this update from Pmgc Holdings Inc.
[{"type":"image","alt":"PMGC Holdings Inc.","displaySize":"","headline":null,"caption":"PMGC Holdings Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":243,"url":"https://media.zenfs.com/en/globenewswire.com/546741842ddd656c130df2366fbdd9a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FeIekmuAEqql.btYh_OPxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/546741842ddd656c130df2366fbdd9a7","width":300,"height":243}},"lazy":false},{"type":"text","content":"NEWPORT BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the filing of four novel patent applications for its two candidates EL-22 and EL-32. These patent applications cover the animal market, as well as treating muscle loss in obese patients, both as standalone and combination therapies alongside GLP-1 receptor agonists.","length":477,"tagName":"p"},{"type":"text","content":"The Company filed the following four patents today:","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"EL-22 in Animals: Fusion Protein of Myo-2 for Use in Encouraging Muscle Growth in Animals (Patent Application No. 19/191,246).","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"EL-32 in Obesity as Monotherapy and Combination with GLP-1: Updated patent filings for Pharmaceutical Composition for Treatment of Muscle Loss Due to Obesity Treatments (Patent Application No. 19/191,209), and Combination Therapy for Treatment of Muscle Loss Due to Obesity Treatments utilizing GLP-1 receptor agonists (Patent Application No. 19/191,226).","length":355,"tagName":"p"}]},{"val":[{"type":"text","content":"EL-32 in Animals: Animal Feed Additive to Encourage Muscle Growth (Patent Application No. 19/191,258).","length":102,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":583,"olType":false},{"type":"text","content":"The Company believes these newly filed patent applications support the development of Northstrive’s engineered probiotic platform, designed to advance human obesity care by preserving muscle mass while reducing fat mass, with additional potential applications in animal health.","length":277,"tagName":"p"},{"type":"text","content":"...